Ocugen Inc (NASDAQ: OCGN) |
|
*Market share is calculated based on total revenue.
News about Ocugen Inc Contracts |
November 19, 2024
The recent announcement from Ocugen, Inc. regarding their preliminary findings from the OCU410 ArMaDa clinical trial sheds light on a potential breakthrough in treating geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). As the prevalence of dAMD continues to rise globally, innovative therapies like OCU410 are pivotal in paving the way for better management of this debilitating condition. Overview of the Study Ocugen s Phase 1/2 OCU410 ArMaDa trial aimed to assess the safety and efficacy of OCU410, a novel modifier gene therapy, in individuals suffering from GA due to dAMD. This initial stage of the trial was focused on dose escalation, a critical step in establishing not only ...
|
August 5, 2024
Precision Medicine Advancements: Ocugen, Inc. s Expanded Access Program for Retinitis Pigmentosa Receives FDA Green LightMALVERN, Pa., Aug. 05, 2024 In a significant stride towards the treatment of retinitis pigmentosa (RP), Ocugen, Inc. (NASDAQ: OCGN), a trailblazing biotechnology company championing novel gene and cell therapies, today announced the U.S. Food and Drug Administration (FDA) has approved its Expanded Access Program (EAP) for OCU400a. This initiative is aimed at adult patients aged 18 and older diagnosed with RP, a debilitating eye condition characterized by progressive vision loss.Retinitis pigmentosa, an inherited disorder, affects approximately 1 in 4,000 people globally, leading to the ...
|
June 20, 2024
Ocugen, Inc. Makes Critical Advances with Phase 3 liMeliGhT Clinical Trial for OCU400; First Patient Successfully DosedMALVERN, Pa., June 20, 2024 In a milestone achievement underscoring its innovative approach to treating retinal diseases, Ocugen, Inc. (NASDAQ: OCGN), a pioneering biotechnology firm specializing in the development and commercialization of cutting-edge gene and cell therapies as well as vaccines, has announced the dosing of the first patient in its pivotal Phase 3 liMeliGhT clinical trial for OCU400. This experimental gene therapy product is being specifically designed to address the multifaceted challenges posed by retinitis pigmentosa (RP).Retinitis pigmentosa is a group of rare genetic...
|
June 5, 2024
Imminent Deadline Approaches for Ocugen Investors to Participate in Securities Class Action, Investigated by Faruqi and Faruqi, LLP New York, June 5, 2024 Faruqi and Faruqi, LLP, a preeminent national securities law firm, is currently undertaking an inquiry into potential claims against Ocugen, Inc. (henceforth referred to as Ocugen or the Company), which is publicly listed on the NASDAQ under the ticker symbol OCGN. Investors are hereby reminded of the looming deadline of June 10, 2024, to motion for the lead plaintiff role in a recently instituted federal securities class action lawsuit against the Company.As a distinguished firm in the realm of securities litigation, Faruqi and Faruqi, LLP brings consid...
|
May 31, 2024
Ocugen Achieves Key Milestones in Advancing Gene Therapy Programs for Geographic Atrophy and Retinitis Pigmentosa MALVERN, Pa., May 31, 2024 - Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a forefront contender in biotechnology dedicated to pioneering novel gene and cell therapies alongside vaccines, has recently made significant progress in its clinical development initiatives. The advancements span two promising gene therapy products OCU410 and OCU400 targeting debilitating eye diseases: geographic atrophy (GA) and retinitis pigmentosa (RP), respectively.Ocugen has ventured into new territory with its cutting-edge OCU410 (AAV5-hRORA), a modifier gene therapy candidate poised to address GA, an advanc...
|
May 28, 2024
The esteemed Pomerantz Law Firm has recently announced the initiation of a class action lawsuit against Ocugen, Inc. (NASDAQ: OCGN). Shareholders who have invested in the company are strongly encouraged to contact Danielle Peyton, a representative of Pomerantz Law Firm, to participate in the legal proceedings. The law firm can be reached at newaction@pomlaw.com or 646-581-9980, or toll-free at 888.4-POMLAW. Those interested in this lawsuit are requested to include their mailing address, telephone number, and the number of shares purchased in their correspondence.The Class Action Lawsuit Against Ocugen, Inc.:Pomerantz Law Firm, known for its dedication to shareholder rights, has taken the initiative to file a...
|
April 10, 2024
In an exciting development for biotechnology company Ocugen, Inc., the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has offered positive scientific advice regarding the approval pathway for OCU400Modifier gene therapy. This therapy targets patients with a broad indication of retinitis pigmentosa (RP), an inherited degenerative eye disease. The review covered the study design, endpoints, and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial, conducted in the United States. The approval for submission of a Marketing Authorization Application (MAA) in Europe signifies a significant milestone for Ocugen.Facts and Assessment:The acceptance of ...
|
April 8, 2024
Ocugen, Inc. Receives FDA Clearance for Phase 3 Clinical Trial of OCU400, the First Gene Therapy for Retinitis PigmentosaGene therapy is an exciting field in biotechnology that holds immense potential for treating a wide range of diseases. Ocugen, Inc., a leading biotechnology company, has recently announced a major milestone in this field with the clearance of an Investigational New Drug (IND) amendment by the U.S. Food and Drug Administration (FDA). This clearance paves the way for the initiation of a Phase 3 clinical trial of OCU400, a groundbreaking modifier gene therapy product candidate for retinitis pigmentosa (RP).Retinitis pigmentosa is a group of rare genetic disorders that result in the progressiv...
|
February 28, 2024
Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company dedicated to the development and commercialization of innovative gene and cell therapies and vaccines, recently announced the availability of its Clinical Showcase webcast on February 21, 2024. This noteworthy event shed light on the cutting-edge advancements in Ocugen s research and development efforts. In this article, we explore the key takeaways from this webcast and delve into the company s potential impact on the field of drug discovery.Webcast Insights:During the Clinical Showcase webcast, Ocugen presented a comprehensive overview of its ongoing research and pipeline. The company s primary focus lies in unraveling the potential of gene and c...
|
January 31, 2024
In what is a landmark development, Ocugen, Inc., a trailblazer in the biotechnology industry specializing in novel gene and cell therapies, has announced its entry on the stage of the Pharma Market Research Conference (PMRC) 2024. The announcement comes straight from the company s headquarters in Malvern, PA., and has been eagerly anticipated by stakeholders in the pharmaceutical and healthcare industry.Dr. Shankar Musunuri, the Chairman, Chief Executive Officer, and Co-founder of Ocugen, is set to deliver the keynote address on Future Innovations in Healthcare: From Dreaming to Community Health at the prestigious PMRC. The conference is scheduled as a two-day event from February 7 to 8, 2024, based at Newar...
|
Publicly Traded Peers of Ocugen Inc
Vbi Vaccines Inc Share Performance
-90.26%
This Year
|
Vbi Vaccines Inc
Profile
Vbi Vaccines Inc is a biopharmaceutical company that focuses on the development and commercialization of a new generation of vaccines and immunotherapies. Their business model revolves around leveraging their proprietary technologies to create innovative products that target a range of infectious diseases and immune-oncology indications. By conducting rigorous research and clinical trials, Vbi Vaccines aims to bring these novel therapies to market and address unmet medical needs.
More about Vbi Vaccines Inc's Market Share
|
Humacyte Inc Share Performance
-8.49%
This Year
|
Humacyte Inc
Profile
Humacyte Inc is a biotechnology company that focuses on creating bioengineered human tissue constructs for numerous medical applications. Their business model revolves around developing and commercializing their proprietary Humacyl platform, which uses a patient's own cells to create acellular scaffolds that mimic human tissue. These tissue constructs can be used for various purposes such as vascular replacements, functional tissues, and potential regenerative medicine therapies.
More about Humacyte Inc 's Market Share
|
Vaxxinity Inc Share Performance
0.00%
Over The Past 5 Days
|
Vaxxinity Inc
Profile
Vaxxinity Inc is a company that operates on a business model that focuses on the development and distribution of vaccines.
More about Vaxxinity Inc 's Market Share
|
Ocular Therapeutix Inc Share Performance
+91.56%
One Year
|
Ocular Therapeutix Inc
Profile
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
More about Ocular Therapeutix Inc 's Market Share
|
Aerie Pharmaceuticals Inc Share Performance
+103.60%
This Year
|
Aerie Pharmaceuticals Inc
Profile
Aerie Pharmaceuticals Inc operates on a business model focused on developing and commercializing innovative treatments for eye diseases. They utilize research and development to create new drugs, which they then bring to market through strategically planned clinical trials and regulatory approval processes. By primarily concentrating on eye-related disorders, Aerie Pharmaceuticals aims to carve a niche in the pharmaceutical industry and provide effective solutions for patients suffering from these conditions.
More about Aerie Pharmaceuticals Inc 's Market Share
|
Regenxbio Inc Share Performance
0.00%
Over The Past 5 Days
|
Regenxbio Inc
Profile
Regenxbio Inc is a biotechnology company that focuses on the development and commercialization of gene therapy treatments for various diseases. Their business model revolves around leveraging their proprietary gene delivery platform, NAV Technology, to license their technology and collaborate with other pharmaceutical companies to advance gene therapy programs. They generate revenue through licensing agreements, milestone payments, and royalties from their partners, while retaining the rights to develop their own internal pipeline of therapies.
More about Regenxbio Inc 's Market Share
|
Eyepoint Pharmaceuticals Inc Share Performance
0.00%
Over The Past 5 Days
|
Eyepoint Pharmaceuticals Inc
Profile
Eyepoint Pharmaceuticals Inc is a pharmaceutical company that operates on a specialty business model focused on advancing ophthalmic therapies. They develop and commercialize innovative treatments using their proprietary drug delivery technology, allowing for sustained release of drugs to the eye. By leveraging their expertise in ophthalmology and controlled release technology, Eyepoint aims to improve patient outcomes and address unmet medical needs in eye care.
More about Eyepoint Pharmaceuticals Inc 's Market Share
|
Adverum Biotechnologies Inc Share Performance
-0.21%
This Year
|
Adverum Biotechnologies Inc
Profile
Adverum Biotechnologies Inc's business model is focused on developing gene therapies using its proprietary platform to deliver therapeutics for eye diseases.
More about Adverum Biotechnologies Inc 's Market Share
|
Nymox Pharmaceutical Corporation Share Performance
-42.73%
This Year
|
Nymox Pharmaceutical Corporation
Profile
Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on the research and development of innovative treatments for various diseases and conditions.
More about Nymox Pharmaceutical Corporation's Market Share
|
Citius Pharmaceuticals Inc Share Performance
0.00%
Over The Past 5 Days
|
Citius Pharmaceuticals Inc
Profile
Citius Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for a wide range of medical conditions. Their business model revolves around identifying unmet medical needs, conducting research and development to create novel drugs, and obtaining regulatory approvals for these drugs to bring them to market. They primarily aim to provide effective treatment options to patients and achieve commercial success through strategic partnerships and collaborations within the pharmaceutical industry.
More about Citius Pharmaceuticals Inc 's Market Share
|
Novaccess Global Inc Share Performance
0.00%
30 Days
|
Novaccess Global Inc
Profile
Novaccess Global Inc's business model revolves around providing innovative access control solutions for various industries. Their offerings range from physical access control systems to cloud-based security solutions, helping organizations enhance their security measures and streamline access management processes.
More about Novaccess Global Inc's Market Share
|
Aura Biosciences Inc Share Performance
-4.15%
This Quarter
|
Aura Biosciences Inc
Profile
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
More about Aura Biosciences Inc 's Market Share
|
Protara Therapeutics Inc Share Performance
0.00%
Over The Past 5 Days
|
Protara Therapeutics Inc
Profile
Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth.
More about Protara Therapeutics Inc's Market Share
|
Bluebird Bio Inc Share Performance
+3.80%
This Year
|
Bluebird Bio Inc
Profile
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
More about Bluebird Bio Inc 's Market Share
|
Denali Therapeutics Inc Share Performance
-15.14%
30 Days
|
Denali Therapeutics Inc
Profile
Denali Therapeutics Inc is a biotechnology company focused on developing and delivering effective therapies for neurodegenerative diseases. Their business model revolves around leveraging their deep knowledge of neurology and genetics to discover and develop innovative drugs. They aim to commercialize these therapies through strategic partnerships with pharmaceutical companies or through independent clinical development.
More about Denali Therapeutics Inc 's Market Share
|
Sources: Ocugen Inc and all companies mentioned above in this report
|